Jon Congleton - 21 Nov 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Executive Officer, Director
Signature: /s/ Adam Levy, Attorney-in-fact
Issuer symbol: MLYS
Transactions as of: 21 Nov 2025
Net transactions value: +$13,004
Form type: 4
Filing time: 24 Nov 2025, 17:07:17 UTC
Previous filing: 13 Nov 2025
Next filing: 13 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Congleton Jon	Chief Executive Officer, Director	150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR	/s/ Adam Levy, Attorney-in-fact	24 Nov 2025	0001644975

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Options Exercise	$13,004	+24,082	+3.8%	$0.5400	655,387	21 Nov 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLYS	Stock Option	Options Exercise	$0	-24,082	-100%	$0.000000	0	21 Nov 2025	Common Stock	24,082	$0.5400	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2	The stock option vested with respect to 25% of the underlying shares on March 12, 2022 and the remaining shares in 36 substantially equal monthly installments thereafter.